sgp130Fc
sgp130Fc, also known as sgp130-Fc or olamkicept, is a recombinant fusion protein designed to selectively inhibit interleukin-6 (IL-6) trans-signaling. It consists of the extracellular portion of the signal transduction receptor gp130 fused to the Fc region of human IgG1, producing a dimeric molecule with properties suitable for therapeutic use.
Mechanism of action: In IL-6 signaling, IL-6 binds to soluble IL-6 receptor (sIL-6R) to form a complex
Development and status: sgp130Fc has been investigated in preclinical models and in early-phase clinical trials for
Structure and pharmacology: The Fc fusion provides dimerization and an extended circulatory half-life via Fc receptor